Martine Simonelig Selected Research

Guanabenz (BR 750)

1/2019	Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy.
1/2011	Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martine Simonelig Research Topics

Disease

5	Oculopharyngeal Muscular Dystrophy 01/2022 - 01/2011
2	Neoplasms (Cancer) 01/2021 - 01/2013
1	Muscular Atrophy (Muscle Atrophy) 01/2022
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 01/2021
1	Fibrosis (Cirrhosis) 01/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2015
1	Late Onset Disorders 03/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2015
1	Muscular Diseases (Myopathy) 04/2011
1	Alzheimer Disease (Alzheimer's Disease) 05/2009

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2009
3	Poly(A)-Binding Protein IIIBA 03/2015 - 05/2009
2	Messenger RNA (mRNA)IBA 01/2021 - 03/2015
2	Guanabenz (BR 750)FDA Link 01/2019 - 01/2011
2	polyalanineIBA 03/2015 - 05/2009
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	UbiquitinIBA 01/2022
1	Piwi-Interacting RNAIBA 01/2021
1	Prion ProteinsIBA 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2013
1	Alanine (L-Alanine)FDA Link 04/2011
1	6-aminophenanthridineIBA 01/2011